Your submission is now a Draft.

Once it's ready, please submit your draft for review by our team of Community Moderators. Thank you!

You have been invited to co-author this question.

When it is ready, the author will submit it for review by Community Moderators. Thanks for helping!


This question now needs to be reviewed by Community Moderators.

We have high standards for question quality. We also favor questions on our core topic areas or that we otherwise judge valuable. We may not publish questions that are not a good fit.

If your question has not received attention within a week, or is otherwise pressing, you may request review by tagging @moderators in a comment.

You have been invited to co-author this question.

It now needs to be approved by Community Moderators. Thanks for helping!


{{qctrl.question.predictionCount() | abbrNumber}} predictions
{{"myPredictionLabel" | translate}}:  
{{ qctrl.question.resolutionString() }}
{{qctrl.question.predictionCount() | abbrNumber}} predictions
My score: {{qctrl.question.player_log_score | logScorePrecision}}
Created by: juancambeiro and
co-authors , {{coauthor.username}}
Healthy Communities Keep Virginia Safe II

Make a Prediction


Two important types of COVID therapeutics are monoclonal antibodies and antivirals.

As of late 2022, the U.S. Food and Drug Administration (FDA) had authorized or approved the use of two monoclonal antibodies (Bebtelovimab and Evusheld) and three antiviral drugs (Veklury/Remdesivir, Paxlovid, and Lagevrio/molnupiravir).

However, the SARS-CoV-2 variants in circulation has raised concerns about the efficacy of these therapeutics, in particular the monoclonal antibodies. On November 30, 2022, the FDA withdrew the authorization for Bebtelovimab and on January 26, 2023, the FDA withdrew authorization for Evusheld.

As of January 27, 2022, Paxlovid, Veklury (remdesivir) and Lagevrio (molnupiravir) continue to remain authorized as COVID therapeutics.

The purpose of this question is to understand the likelihood of there no longer being any authorized monoclonal antibodies or antivirals in the U.S. in 2023.